Skip to main content

CAMZYOS® Dosing

The CAMZYOS Dosing Guide provides considerations to assist doctors in determining the appropriate dose for each patient at key points in their treatment with CAMZYOS. The dosing guide follows the FDA-approved labeling, which can be viewed here.

Dosing Initiation and Maintenance for All Patients1

*Additional echocardiograms may also be needed after a change in the dose of CAMZYOS, a treatment interruption, and/or after starting certain medications that are known to affect CAMZYOS (weak to moderate CYP2C19 or moderate to strong CYP3A4 inhibitors).1

A simplified visualization of the number of echos required for treatment with CAMZYOS is captured above. Please see detailed guidance in the Dosing and Administration section of the US Prescribing Information. Additional echocardiograms may also be needed after a change in the dose of CAMZYOS, a treatment interruption, and/or after starting certain medications that are known to affect CAMZYOS (weak to moderate CYP2C19 or moderate to strong CYP3A4 inhibitors).

Prior to initiating CAMZYOS1:

  • Confirm absence of pregnancy and usage of effective contraception in females of reproductive potential. Advise females of reproductive potential to use effective contraception until 4 months after the last dose. Use a contraceptive not affected by CAMZYOS’ CYP 450 enzyme induction or add nonhormonal contraception
  • Assess left ventricular ejection fraction (LVEF) by echocardiogram (echo). Do not initiate treatment in patients with LVEF <55%
  • Assessment of postexercise LVOT gradient may be considered in symptomatic patients with normal or near normal Valsalva gradients
  • Consider contraindications and drug interactions prior to and throughout treatment
  • In order to prescribe CAMZYOS, you must be certified in the CAMZYOS Risk Evaluation and Mitigation Strategy (REMS) program. If you are not certified, you can learn more here

Following initiation1:

  • Patients may develop heart failure while taking CAMZYOS. Regular LVEF and Valsalva LVOT gradient assessment is required for careful dose titration to achieve an appropriate target Valsalva LVOT gradient while maintaining LVEF ≥50% and avoiding heart failure symptoms

For Pediatric Patients, Dosing is Based on Weight1

Initial Dose*

Patients ≥45 kg: 5 mg

Patients 30 to <45 kg: 2.5 mg

*In pediatric patients who are on stable therapy with a moderate CYP2C19 inhibitor or a strong CYP3A4 inhibitor, initiate CAMZYOS at one dose level below the recommended starting dose: 2.5 mg for patients weighing 45 kg or more, or 1 mg for patients weighing 30 kg to less than 45 kg.1

  • The CAMZYOS 1 mg dose strength is anticipated to be available in mid-December 2026.
Prescribing CAMZYOS

CAMZYOS Interactive Dosing Guide

Information on concomitant administration of weak to moderate CYP2C19 or moderate to strong CYP3A4 inhibitors with CAMZYOS can be found here.

Find dosing regimens for our medicines

Find dosing regimens for our medicines


  • Delay dose increases when there is intercurrent illness (eg, serious infection) or arrhythmia (eg, atrial fibrillation or other uncontrolled tachyarrhythmia) that may impair systolic function. Consider interruption of CAMZYOS in patients with an intercurrent illness1
  • CAMZYOS can be taken without regard to food. If a dose is missed, it should be taken as soon as possible, and the next scheduled dose should be taken at the usual time the following day. Exact timing of dosing during the day is not essential, but 2 doses should not be taken on the same day. CAMZYOS capsules should be taken whole. Advise patients not to break, open, or chew the capsules1
* The 1 mg dose is not recommended for patients ≥18 years of age.1
† In patients ≥18 years of age who are on stable therapy with a moderate CYP2C19 inhibitor or a strong CYP3A4 inhibitor, initiate CAMZYOS at 2.5 mg orally once daily.1

CYP=cytochrome P450; echo=echocardiogram; FDA=US Food and Drug Administration; LVEF=left ventricular ejection fraction; LVOT=left ventricular outflow tract.

In EXPLORER-HCM, Adult Patients Were Distributed Across Dose Levels by Week 30 Based on Individual Response

Scheduled dose assessments of CAMZYOS in EXPLORER-HCM occurred at Weeks 8 and 14 based on Valsalva gradient, plasma concentration, and LVEF.1,4

82% of patients were on 5 mg or 10 mg at Week 301

Dose distribution at Week 30 derived from EXPLORER-HCM trial.1
*3 patients in the CAMZYOS group discontinued treatment prior to Week 30 (due to atrial fibrillation, syncope, and study withdrawal; all n=1).4
LVEF=left ventricular ejection fraction.

In SCOUT-HCM, initial CAMZYOS dosing for pediatric patients was based on weight3

91% of patients started on the 5 mg once daily dose5

9% started on the 2.5 mg once daily dose5

Checklist

The Echocardiogram Schedule Tool is available to help estimate the date ranges for a patient’s echocardiograms in initiation phase, as required by the CAMZYOS REMS Program. Delayed or missed visits may lead to interruption or discontinuation of treatment. To use the tool, visit www.CAMZYOSechotool.com.

Please review for additional information.

  • CAMZYOS is primarily metabolized by CYP2C19 and, to a lesser extent, by CYP3A4 and CYP2C9. Concomitant use of CAMZYOS with drugs that interact with these enzymes may lead to life-threatening drug interactions, such as heart failure or loss of effectiveness
  • The use of moderate to strong inducers and inhibitors of CYP2C19 and moderate to strong inducers and inhibitors of CYP3A4 may affect the exposures of CAMZYOS
  • Please see the table below for detailed descriptions of drug interactions, prevention and management strategies, and their clinical impact

Established and Potentially Significant Pharmacokinetic Drug Interactions with CAMZYOS1

CategoryDrug typePrevention or managementClinical impact
Impact of other drugs on CAMZYOS  Strong CYP2C19 inhibitors
Concomitant use is contraindicated.Concomitant use increases CAMZYOS exposure, which may increase the risk of heart failure due to systolic dysfunction.
Moderate to strong CYP2C19 inducers

or

Moderate to strong CYP3A4 inducers
Concomitant use is contraindicated.
  • Concomitant use decreases CAMZYOS exposure, which may reduce the efficacy of CAMZYOS
  • The risk of heart failure due to systolic dysfunction may increase with discontinuation of these inducers as the levels of induced enzyme normalizes
Weak CYP2C19 inhibitors

or

Moderate CYP3A4 inhibitors
  • Initiate CAMZYOS at the recommended starting dosage in patients who are on stable therapy with a weak CYP2C19 or moderate CYP3A4 inhibitor
  • Reduce dose of CAMZYOS to the next lower daily (mg) dose [ie, 15 mg to 10 mg, 10 mg to 5 mg, 5 mg to 2.5 mg, or 2.5 mg to 1 mg (pediatric)] in patients who are on CAMZYOS treatment and intend to initiate a weak CYP2C19 inhibitor or a moderate CYP3A4 inhibitor.
  • Avoid inititation of concomitant weak CYP2C19 and moderate CYP3A4 inhibitors in patients who are on the lowest recommended dose of CAMZYOS
  • For short-term use (eg, 1 week), interrupt CAMZYOS for the duration of treatment with a weak inhibitor of CYP2C19 or a moderate inhibitor of CYP3A4. CAMZYOS may be reinitiated at the previous dose immediately on discontinuation of a concomitant therapy
Concomitant use increases CAMZYOS exposure, which may increase the risk of adverse drug reactions.
Moderate CYP2C19 inhibitors

or

strong CYP3A4 inhibitors
  • Initiate CAMZYOS at one dose below the recommended starting dose in patients who are on stable therapy with a moderate CYP2C19 inhibitor or a strong CYP3A4 inhibitor
  • Reduce dose of CAMZYOS to the next lower daily (mg) dose [ie, 15 mg to 10 mg; 10 mg to 5 mg; 5 mg to 2.5 mg; or 2.5 mg to 1 mg (pediatric)] in patients who are on CAMZYOS and intend to initiate a moderate CYP2C19 inhibitor or a strong CYP3A4 inhibitor.
  • Avoid initiation of concomitant moderate CYP2C19 and strong CYP3A4 inhibitors in patients who are on the lowest recommended dose of CAMYZOS
  • An increase in dose of CAMZYOS may be needed if the moderate inhibitor of CYP2C19 or strong inhibitor of CYP3A4 is discontinued after long-term concomitant use. Monitor for new or worsening symptoms
  • For short-term use (eg, 1 week), interrupt CAMZYOS for the duration of treatment with a moderate inhibitor of CYP2C19 or a strong inhibitor of CYP3A4. CAMZYOS may be reinitiated at the previous dose immediately on discontinuation of concomitant therapy
  • Concomitant use increases CAMZYOS exposure, which may increase the risk of adverse drug reactions
  • Discontinuing inhibitor use after long-term concomitant use may decrease CAMZYOS exposure, which may reduce the efficacy of CAMZYOS
Impact of CAMZYOS on other drugsCYP3A4, CYP2C9,
and
CYP2C19 substrates
  • Closely monitor patients when CAMZYOS is used with concomitant CYP3A4, CYP2C9 or CYP2C19 substrates unless otherwise recommended in the Prescribing Information
  • CHCs containing a combination of ethinyl estradiol and norethindrone may be used with CAMZYOS, but if other CHCs are used, advise patients to add nonhormonal contraception (such as condoms) or use an alternative contraceptive method that is not affected by CYP450 enzyme induction (eg, intrauterine system) during concomitant use and for 4 months after the last dose of CAMZYOS
  • CAMZYOS is an inducer of CYP3A4, CYP2C9, and CYP2C19
  • Concomitant use with CYP3A4, CYP2C9, or CYP2C19 substrates may reduce the plasma concentration of these drugs
  • Concomitant use of CAMZYOS with hormonal contraceptives (progestin and ethinyl estradiol), which are CYP3A4 substrates, may decrease exposures of certain progestins, which may lead to contraceptive failure
Impact of drugs that reduce cardiac contractilityDrugs that reduce cardiac contractilityIf concomitant therapy with a negative inotrope is initiated, or if the dose of a negative inotrope is increased, monitor LVEF closely until stable doses and clinical response have been achieved.
  • Expect additive negative inotropic effects of CAMZYOS and other drugs that reduce cardiac contractility
  • Avoid concomitant use of CAMZYOS in patients on disopyramide, ranolazine, verapamil with a beta blocker, or diltiazem with a beta blocker as these medications and combinations increase the risk of left ventricular systolic dysfunction and heart failure symptoms and clinical experience is limited

Advise patients of the potential for drug interactions, including with over-the-counter medications (such as omeprazole, esomeprazole, or cimetidine).
Advise patients to inform their healthcare providers of all concomitant products prior to and during treatment with CAMZYOS.1

 

CHC=combined hormonal contraception; CYP=cytochrome P450; LVEF=left ventricular ejection fraction.

References:

  1. CAMZYOS [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2026.
  2. CAMZYOS REMS. Patient Status Form. Accessed April 18, 2025. https://www.camzyosrems.com/assets/commercial/us/camzyosrems/en/pdf/Camzyos-Patient-Status-Form.pdf
  3. Rossano JW, Canter C, Wolf CM, et al. Mavacamten in adolescents with obstructive hypertrophic cardiomyopathy. N Engl J Med. 2026;395(4):362-373.
  4. Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10253):759-769.
  5. Rossano JW, Canter C, Wolf CM, et al. Mavacamten in adolescents with obstructive hypertrophic cardiomyopathy. N Engl J Med. 2026;395(4):362-373 [supplementary appendix].


© 2026 MyoKardia, Inc., a Bristol Myers Squibb company. 
CAMZYOS® and the CAMZYOS and MyCAMZYOS Logos are trademarks of MyoKardia, Inc.


3500-US-2600359   10/26

This site is intended for U.S. Healthcare Professionals only.